NEW SYNTHETIC TLR9 AGONISTS Russian patent published in 2012 - IPC A61K48/00 A61K39/00 A61P37/02 C07H21/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention described immunomodulatory compounds of oligonucleotides individually providing unique profiles of cytokines and chemokines by relation as TLR agonists. The TLP9 agonists aim at modulation of immune responses mediated by Toll-like receptor (TLR). There are also described a composition containing an immunomodulatory compound and a physiologically acceptable carrier and enables producing an immune response in a patient, a method for producing the immune response in the patient with the use of the immunomodulatory compound, methods of therapeutic and preventive treatment in the patient in need of modulation of the immune response, particularly in cancer, autoimmune and inflammatory disorders, an infectious disease, allergy, asthma and other diseases. The immunomodulatory compounds may be used in a combination with other therapeutic agents and chemotherapeutic compounds used in specific diseases or disorders.

EFFECT: compounds under the invention create such specific modulations of the immune response different from modulations created by non-methylated dinucleotides CpG.

9 cl, 35 dwg, 2 tbl, 5 ex